Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Squamous Cell 1Neoplasms 1Microsatellite Instability 1Mesothelioma, Malignant 1Meningioma 1

Interventions

pembrolizumab 7Ipilimumab 5Nivolumab 4fludarabine 3Radiosurgery 3Drug Therapy 3Cyclophosphamide 3spartalizumab 2aldesleukin 2Sirolimus 2Riluzole 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oncolytic Virotherapy 2Counseling 2Bupropion 2Blood Specimen Collection 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tocilizumab 1sargramostim 1saracatinib 1pertuzumab 1pazopanib 1liposomal doxorubicin 1ixabepilone 1fostamatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × fludarabine phosphate × Thoracic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡